The Acidic Domain of the Endothelial Membrane Protein GPIHBP1 Stabilizes Lipoprotein Lipase Activity by Preventing Unfolding of Its Catalytic Domain

Overview

Journal Elife

Specialty Biology

Date 2016 Jan 4

PMID 26725083

Citations 60

Authors

Simon Mysling

Kristian Kolby Kristensen

Mikael Larsson

Anne P Beigneux

Henrik Gardsvoll

Loren G Fong

Andre Bensadouen

Thomas Jd Jorgensen

Stephen G Young

Michael Ploug

Affiliations

Soon will be listed here.

Abstract

GPIHBP1 is a glycolipid-anchored membrane protein of capillary endothelial cells that binds lipoprotein lipase (LPL) within the interstitial space and shuttles it to the capillary lumen. The LPL•GPIHBP1 complex is responsible for margination of triglyceride-rich lipoproteins along capillaries and their lipolytic processing. The current work conceptualizes a model for the GPIHBP1•LPL interaction based on biophysical measurements with hydrogen-deuterium exchange/mass spectrometry, surface plasmon resonance, and zero-length cross-linking. According to this model, GPIHBP1 comprises two functionally distinct domains: (1) an intrinsically disordered acidic N-terminal domain; and (2) a folded C-terminal domain that tethers GPIHBP1 to the cell membrane by glycosylphosphatidylinositol. We demonstrate that these domains serve different roles in regulating the kinetics of LPL binding. Importantly, the acidic domain stabilizes LPL catalytic activity by mitigating the global unfolding of LPL's catalytic domain. This study provides a conceptual framework for understanding intravascular lipolysis and GPIHBP1 and LPL mutations causing familial chylomicronemia.

Citing Articles

Polysorbates degrading enzymes in biotherapeutics - a current status and future perspectives.

Felix M, Waerner T, Lakatos D, Reisinger B, Fischer S, Garidel P Front Bioeng Biotechnol. 2025; 12:1490276.

PMID: 39867473 PMC: 11760601. DOI: 10.3389/fbioe.2024.1490276.

Lipoprotein Lipase: Structure, Function, and Genetic Variation.

Perera S, Wang J, McIntyre A, Hegele R Genes (Basel). 2025; 16(1).

PMID: 39858602 PMC: 11764694. DOI: 10.3390/genes16010055.

Competitive displacement of lipoprotein lipase from heparan sulfate is orchestrated by a disordered acidic cluster in GPIHBP1.

Biswas A, Arshid S, Kristensen K, Jorgensen T, Ploug M J Lipid Res. 2025; 66(2):100745.

PMID: 39814316 PMC: 11869522. DOI: 10.1016/j.jlr.2025.100745.

A negatively charged cluster in the disordered acidic domain of GPIHBP1 provides selectivity in the interaction with lipoprotein lipase.

Risti R, Reimund M, Seeba N, Lookene A Sci Rep. 2024; 14(1):19639.

PMID: 39179764 PMC: 11344153. DOI: 10.1038/s41598-024-70468-6.

Macromolecular Interactions of Lipoprotein Lipase (LPL).

Wheless A, Gunn K, Neher S Subcell Biochem. 2024; 104:139-179.

PMID: 38963487 DOI: 10.1007/978-3-031-58843-3_8.

References

Gardsvoll H, Hansen L, Jorgensen T, Ploug M . A new tagging system for production of recombinant proteins in Drosophila S2 cells using the third domain of the urokinase receptor. Protein Expr Purif. 2007; 52(2):384-94. DOI: 10.1016/j.pep.2006.11.013. View

Beigneux A, Davies B, Gin P, Weinstein M, Farber E, Qiao X . Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007; 5(4):279-91. PMC: 1913910. DOI: 10.1016/j.cmet.2007.02.002. View

Gin P, Yin L, Davies B, Weinstein M, Ryan R, Bensadoun A . The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J Biol Chem. 2008; 283(43):29554-62. PMC: 2662032. DOI: 10.1074/jbc.M802579200. View

Beigneux A, Franssen R, Bensadoun A, Gin P, Melford K, Peter J . Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol. 2009; 29(6):956-62. PMC: 2811263. DOI: 10.1161/ATVBAHA.109.186577. View

Lin L, Gardsvoll H, Huai Q, Huang M, Ploug M . Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem. 2010; 285(14):10982-92. PMC: 2856303. DOI: 10.1074/jbc.M109.093492. View

Olivecrona G, Ehrenborg E, Semb H, Makoveichuk E, Lindberg A, Hayden M . Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res. 2009; 51(6):1535-45. PMC: 3035517. DOI: 10.1194/jlr.M002717. View

Davies B, Beigneux A, Barnes 2nd R, Tu Y, Gin P, Weinstein M . GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 2010; 12(1):42-52. PMC: 2913606. DOI: 10.1016/j.cmet.2010.04.016. View

Voss C, Davies B, Tat S, Gin P, Fong L, Pelletier C . Mutations in lipoprotein lipase that block binding to the endothelial cell transporter GPIHBP1. Proc Natl Acad Sci U S A. 2011; 108(19):7980-4. PMC: 3093490. DOI: 10.1073/pnas.1100992108. View

Beigneux A, Davies B, Tat S, Chen J, Gin P, Voss C . Assessing the role of the glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) three-finger domain in binding lipoprotein lipase. J Biol Chem. 2011; 286(22):19735-43. PMC: 3103352. DOI: 10.1074/jbc.M111.242024. View

10.

Gardsvoll H, Jacobsen B, Kriegbaum M, Behrendt N, Engelholm L, Ostergaard S . Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. J Biol Chem. 2011; 286(38):33544-56. PMC: 3190949. DOI: 10.1074/jbc.M111.220087. View

11.

Kriegbaum M, Persson M, Haldager L, Alpizar-Alpizar W, Jacobsen B, Gardsvoll H . Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr Drug Targets. 2011; 12(12):1711-28. DOI: 10.2174/138945011797635812. View

12.

Xu X, Gardsvoll H, Yuan C, Lin L, Ploug M, Huang M . Crystal structure of the urokinase receptor in a ligand-free form. J Mol Biol. 2012; 416(5):629-41. DOI: 10.1016/j.jmb.2011.12.058. View

13.

Rios J, Shastry S, Jasso J, Hauser N, Garg A, Bensadoun A . Deletion of GPIHBP1 causing severe chylomicronemia. J Inherit Metab Dis. 2011; 35(3):531-40. PMC: 3319888. DOI: 10.1007/s10545-011-9406-5. View

14.

Gin P, Goulbourne C, Adeyo O, Beigneux A, Davies B, Tat S . Chylomicronemia mutations yield new insights into interactions between lipoprotein lipase and GPIHBP1. Hum Mol Genet. 2012; 21(13):2961-72. PMC: 3373243. DOI: 10.1093/hmg/dds127. View

15.

Uversky V . Size-exclusion chromatography in structural analysis of intrinsically disordered proteins. Methods Mol Biol. 2012; 896:179-94. DOI: 10.1007/978-1-4614-3704-8_11. View

16.

Surendran R, Visser M, Heemelaar S, Wang J, Peter J, Defesche J . Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med. 2012; 272(2):185-96. PMC: 3940136. DOI: 10.1111/j.1365-2796.2012.02516.x. View

17.

Mertens H, Kjaergaard M, Mysling S, Gardsvoll H, Jorgensen T, Svergun D . A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). J Biol Chem. 2012; 287(41):34304-15. PMC: 3464537. DOI: 10.1074/jbc.M112.398404. View

18.

Young S, Zechner R . Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev. 2013; 27(5):459-84. PMC: 3605461. DOI: 10.1101/gad.209296.112. View

19.

Gardsvoll H, Kriegbaum M, Hertz E, Alpizar-Alpizar W, Ploug M . The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia. J Histochem Cytochem. 2013; 61(11):802-13. PMC: 3808577. DOI: 10.1369/0022155413501879. View

20.

Larsson M, Vorrsjo E, Talmud P, Lookene A, Olivecrona G . Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem. 2013; 288(47):33997-34008. PMC: 3837139. DOI: 10.1074/jbc.M113.495366. View